¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"immunoglobulin M formation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunoglobulin
    ¸é¿ª±Û·ÎºÒ¸°
  • immunoglobulin (Ig) gene
    ¸é¿ª±Û·ÎºÒ¸° À¯ÀüÀÚ
  • immunoglobulin A
    ¸é¿ª±Û·ÎºÒ¸° A
  • immunoglobulin A deficiency
    ¸é¿ª±Û·ÎºÒ¸° A °áÇÌ(Áõ)
  • immunoglobulin D
    ¸é¿ª±Û·ÎºÒ¸° D
  • immunoglobulin E
    ¸é¿ª±Û·ÎºÒ¸° E
  • immunoglobulin G
    ¸é¿ª±Û·ÎºÒ¸° G
  • immunoglobulin G CSF/serum ratio
    ¸é¿ª±Û·ÎºÒ¸° G ³úô¼ö¾×/Ç÷û ºñ(À²)
  • immunoglobulin G index
    ¸é¿ª±Û·ÎºÒ¸° G Áö¼ö
  • immunoglobulin M
    ¸é¿ª±Û·ÎºÒ¸° M
  • immunoglobulin a nephropathy
    ¸é¿ª±Û·ÎºÒ¸°A½Åº´Áõ(Øó湡­ãìÜ»ñø)
  • immunoglobulin a(iga)
    ¸é¿ª±Û·ÎºÒ¸° A(Øó湡­)
  • immunoglobulin class
    ¸é¿ª±Û·ÎºÒ¸°Å¬·¡½º.
  • immunoglobulin cleavage
    ¸é¿ª±Û·ÎºÒ¸°ºÐÇÒ
  • immunoglobulin detection
    ¸é¿ª±Û·ÎºÒ¸°°ËÃâ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • immunoglobulin receptor
    ¸é¿ª±Û·ÎºÒ¸° ¼ö¿ëü
  • immunoglobulin structure
    ¸é¿ª±Û·ÎºÒ¸° ±¸Á¶
  • immunoglobulin subclass
    ¸é¿ª±Û·ÎºÒ¸°¼­ºêŬ·¡½º.
  • immunoglobulin subgroup analysis
    ¸é¿ª±Û·ÎºÒ¸°¾ÆÇüºÐ¼®
  • immunoglobulin supergene family
    ¸é¿ª±Û·ÎºÒ¸° À¯ÀüÀÚÃʰŴëÁý´Ü
  • immunoglobulin, surface
    ¼¼Æ÷Ç¥¸é ¸é¿ª±Û·ÎºÒ¸°
  • immunoglobulin-coated erythrocyte
    ¸é¿ª±Û·ÎºÒ¸°ºÎÂøÀûÇ÷±¸
  • isotype of immunoglobulin
    ¸é¿ª±Û·ÎºÒ¸°µ¿Á¾Çü
  • monoclonal immunoglobulin
    ´ÜÀÏŬ·Ð¸é¿ª±Û·ÎºÒ¸°
  • monoclonal immunoglobulin detection
    ´ÜÀÏŬ·Ð¸é¿ª±Û·ÎºÒ¸°°ËÃâ
  • monoclonal immunoglobulin disorders
    ´Ü(ÀÏ)Ŭ·Ð¼º ¸é¿ª±Û·ÎºÒ¸°ÀÌ»ó.
  • monoclonal immunoglobulin disorders
    ´Ü(ÀÏ)Ŭ·Ð¼º ¸é¿ª±Û·ÎºÒ¸°ÀÌ»ó.
  • monoclonal immunoglobulin disorders
    ´Ü(ÀÏ)Ŭ·Ð¼º ¸é¿ª±Û·ÎºÒ¸°ÀÌ»ó.
  • monoclonal immunoglobulin disorders
    ´Ü(ÀÏ)Ŭ·Ð¼º ¸é¿ª±Û·ÎºÒ¸°ÀÌ»ó.
  • polyclonal immunoglobulin
    ´ÙŬ·Ð¼º¸é¿ª±Û·ÎºÒ¸°
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
PRF partial reinforcement; patient report form; perforin; plasma recognition factor; pontine reticular f...
PRRF paramedian pontine reticular formation
SNF sinus node formation; skilled nursing facility
TFT thin-film transistor; thrombus formation time; thyroid function test; tight filum terminale; trifluo...
AH   1) Atrial Hypertrophy
  2) Anti-Hyaluronidase
  3) Amyloid imm...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MRF medullary reticular formation
MRF midbrain reticular formation
PPRF paramedial pontine reticular formation
Rf recticular formation
Ig Anti-immunoglobulin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • reticular activating formation
    ¸Á»ó Ȱ¼º°è
  • rosette formation
    ·ÎÁ¦Æ® Çü¼º
  • secondary dentin formation
    ÀÌÂ÷ »ó¾ÆÁú Çü¼º
    Åë»óÀûÀÎ ±â´ÉÀû ±×¸®°í ¿­ ÀûÀÎ Àڱؿ¡ ´ëÇÑ Á¡Â÷ÀûÀÎ Ãß°¡Àû »ó¾ÆÁú Çü¼ºÀÌ¸ç ¹æ»ç¼± »çÁø »óÀ¸·Î Ä¡°üºÎ »ó¾ÆÁú µÎ²²ÀÇ ±ÕÀÏÇÑ Áõ°¡ ¾ç»óÀ» º¸À̰í ÀÖ´Ù. ´ëºÎºÐÀÇ ¼ºÀο¡´Â ÀÌ·¯ÇÑ °úÁ¤ÀÌ Á¸ÀçÇϸç ÀÌÀÇ Á¤µµ´Â °³Àο¡ µû¶ó ´Ù¾çÇÏ´Ù. 2Â÷ »ó¾ÆÁúÀº Ä¡¾Æ Ç¥¸é¿¡¼­ Ä¡¼ö±îÁö ¿ì½Ä º´º¯ÀÌ ÁøÇàµÇ´Âµ¥ °É¸®´Â ½Ã°£°ú °Å¸®¸¦ Áõ°¡½ÃŰ°Ô µÈ´Ù. ¶ÇÇÑ Ä¡¼ö°¢°ú °°Àº Ç¥ÃþÀÇ Ä¡¼ö Á¶Á÷À» ¸ÍÃâ ÈÄ ¼ö³â À̳»¿¡ 2Â÷ »ó¾ÆÁú·Î ´ëÄ¡½ÃÅ´À¸·Î½á ¼öº¹ ½Ã¼ú ½Ã ±â°èÀûÀÎ Ä¡¼ö ³ëÃâ °¡´É¼ºÀ» °¨¼Ò½ÃŲ´Ù. ÇÑÆí Àڱؿ¡ ´ëÇÑ Ä¡¼öÀÇ ¹Î°¨¼ºÀ» °¨¼Ò½Ã۱⠶§¹®¿¡ Ä¡¼ö °Ë»ç¿Í Ä¡¾Æ ÁúȯÀÇ Áø´Ü ½Ã À̰ÍÀÌ °í·ÁµÇ¾î¾ß ÇÑ´Ù.
  • thrombus formation
    Ç÷Àü Çü¼º
  • valve formation
    ÆÇ¸· Çü¼º, ÆÇ Çü¼º
  • whitish formation
    ¹é»ö Çü¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
immunoglobulin A <immunology> Major class of immunoglobulin of external secretions in mammals, also found in serum and body fluids such as tears and saliva and in the respiratory, reproductive, urinary and gastrointestinal tracts.
Immunoglobulin A protects the bodys mucosal surfaces from infection and in secretions, it is found as a dimer (400 kD) joined by a short J chain and linked to a secretory portion or transport piece. In serum found as a monomer (170 kD).
Immunoglobulin A is the main mechanism for providing local immunity against infections in the gut or respiratory tract and may act by reducing the binding between an immunoglobulin A coated micro organism and a host epithelial cell. Present in human colostrum but not transferred across the placenta. Have heavy chains.
(30 Mar 1998)
immunoglobulin allotypes Hereditary serologic types based on antigenic differences in the light and heavy chains of immunoglobulins due to allelic genes in the gene loci coding the chains. The inv system applies to the kappa light chains, the gm system applies to the heavy chains of IgG.
(12 Dec 1998)
immunoglobulin class switching Gene rearrangement of the b-lymphocyte which results in a substitution in the type of heavy-chain constant region that is expressed. This allows the effector response to change while the antigen binding specificity (variable region) remains the same. The majority of class switching occurs by a DNA recombination event but it also can take place at the level of RNA processing.
(12 Dec 1998)
immunoglobulin constant region That region of the immunoglobulin (antibody) molecule that is invariable in its amino acid sequence within any class of immunoglobulins. It confers the biological specificity to the ig and is grossly species specific. It comprises the c-terminus half of the light chains and three quarters or more of the heavy chains, all of the fc fragment, and the c-terminus half of the fab fragment.
(12 Dec 1998)
immunoglobulin D <immunology> This immunoglobulin (184 kD) is present at a low level (3-400 mcg/ml) but is a major immunoglobulin on the surface of B lymphocytes where it may play a role in antigen recognition.
Its structure resembles that of immunoglobulin G but the heavy chains are of the delta type.
(30 Mar 1998)
immunoglobulin domains Structural units of immunoglobulin heavy or light chains that are composed of approximately 110 amino acids. Light chains of an immunoglobulin are composed of one constant domain and one variable domain. Heavy chains are composed of either three or four constant domains and one variable domain.
(05 Mar 2000)
immunoglobulin E <immunology> Class of immunoglobulin (188 kD) associated with immediate type hypersensitivity reactions and helminth infections.
Present in very low amounts in serum and mostly bound to mast cells and basophils that have an immunoglobulin E specific Fc receptor (FceR). Immunoglobulin E has a high carbohydrate content and is also present in external secretions.
Heavy chain of epsilon type.
(30 Mar 1998)
immunoglobulin electrophoresis <immunology, investigation> A test that detects and measures the various immunoglobulins in the blood.
In the normal assay no monoclonal antibodies are detected but in multiple myeloma and chronic lymphocytic leukaemia a single clone of lymphocytes can produce one type of immunoglobulin that is detected in the electrophoresis as monoclonal (made by one cell clone).
(30 Mar 1998)
immunoglobulin G <immunology> The classical immunoglobulin class also called 7S IgG (150 kD).
Composed of two identical light and two identical heavy chains, the constant region sequence of the heavy chains being of the type. The molecule can be described in another way as being composed of two Fab and an Fc fragment.
The Fabs include the antigen combining sites, the Fc region consists of the remaining constant sequence domains of the heavy chains and contains cell binding and complement binding sites.
Immunoglobulin Gs act on pathogens by agglutinating them, by opsonising them, by activating complement mediated reactions against cellular pathogens and by neutralising toxins. They can pass across the placenta to the foetus as maternal antibodies, unlike other Ig classes. In humans four main subclasses are known, IgG2 differs from the rest in not being transferred across the placenta and IgG4 does not fix complement. Immunoglobulin G is present at 8-16 mg/ml in serum.
Synonym: gamma globulin.
(30 Mar 1998)
immunoglobulin gm allotypes Hereditary allotypic markers associated with the heavy chain of IgG.
(12 Dec 1998)
immunoglobulin G subclass deficiency A rare inherited disorder in which there are reduced levels of one or more IgG subclasses resulting from defective heavy chain genes or an abnormality in the regulation of immunoglobulin isotype switching.
(05 Mar 2000)
immunoglobulin idiotypes Unique, genetically controlled determinants present on antibodies whose specificity is limited to a single group of proteins (e.g., another antibody molecule or an individual myeloma protein). The idiotype appears to represent the antigenicity of the antigen-binding site of the antibody and to be genetically codetermined with it. The idiotypic determinants have been precisely located to the variable regions of both immunoglobin polypeptide chains.
(12 Dec 1998)
immunoglobulin inv allotypes Hereditary allotypic markers associated with the light chain of IgG.
(12 Dec 1998)
immunoglobulin isotypes The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties.
(12 Dec 1998)
immunoglobulin joining region Segment of light and heavy chains of mouse and human immunoglobulins where the genes for the variable region upstream join those of the constant region downstream (an important part of the antibody diversity mechanism). In the joining region of the light chain are the genes coding for amino acids 96 to 107.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á